{"id":"double-blind-control-period-a140","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Dehydration"}]},"_chembl":{"chemblId":"CHEMBL5805487","moleculeType":null,"molecularWeight":"493.61"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, A140 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly effective in treating type 2 diabetes.","oneSentence":"A140 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:49.395Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04835142","phase":"PHASE3","title":"Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC","status":"COMPLETED","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2020-12-31","conditions":"Metastatic Colorectal Cancer","enrollment":688}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["KL-140"],"phase":"phase_3","status":"active","brandName":"Double blind control period A140","genericName":"Double blind control period A140","companyName":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","companyId":"sichuan-kelun-biotech-biopharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A140 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}